Third Quarter Highlights
(all comparisons made to the
-
Net sales of
$3.7B , a 26% increase; including 5% organic volume growth -
Operating income of
$343M ; Operating EBITDA of$565M -
Net income per share (EPS) of
$1.40 ; Adjusted EPS up 1% to$1.53 -
Increasing operating EBITDA guidance for fiscal 2021 to
$2.26B - Reaffirming fiscal 2021 organic volume growth of +5%
Berry’s Chairman and CEO
“Again, we have delivered on our strategic goals of driving organic growth and improving our balance sheet, on top of a very strong prior year quarter. We continue to invest in each of our businesses to build and maintain our world-class, low-cost, manufacturing base, with an emphasis on key growth markets and regions and continue to see incremental opportunity to invest organically in support of our unwavering commitment to global growth. The continued positive momentum from our investments in areas such as health and wellness, e-commerce, and food safety along with the focus on growing our emerging market exposure and driving more sustainable packaging, provide us the path to realize long-term consistent volume and earnings growth.”
Consolidated Overview |
|
|
|||
|
|
|
|
||
(in millions of dollars) |
Current |
Prior |
$ Change |
% Change |
|
Net sales |
|
|
|
|
26% |
Operating income |
343 |
347 |
(4 |
) |
(1)% |
The net sales growth is primarily attributed to increased selling prices of
The operating income decrease is primarily attributed to a
|
|
||||
|
|
|
|
||
(in millions of dollars) |
Current |
Prior |
$ Change |
% Change |
|
Net sales |
|
|
|
|
21% |
Operating income |
79 |
80 |
(1 |
) |
(1)% |
The net sales growth in the
The operating income decrease is primarily attributed to a
|
|
||||
|
|
|
|
||
(in millions of dollars) |
Current |
Prior |
$ Change |
% Change |
|
Net sales |
|
|
|
|
32% |
Operating income |
76 |
78 |
(2 |
) |
(3)% |
The net sales growth in the
The operating income decrease is primarily attributed to a
Health, Hygiene & Specialties |
|
|||
|
|
|
|
|
(in millions of dollars) |
Current |
Prior |
$ Change |
% Change |
Net sales |
|
|
|
24% |
Operating income |
113 |
95 |
18 |
19% |
The net sales growth in the Health, Hygiene & Specialties segment is primarily attributed to organic volume growth of 1%, increased selling prices of
The operating income increase is primarily attributed to a
Engineered Materials |
|
||||
|
|
|
|
||
(in millions of dollars) |
Current |
Prior |
$ Change |
% Change |
|
Net sales |
|
|
|
|
31% |
Operating income |
75 |
94 |
(19 |
) |
(20)% |
The net sales growth in the Engineered Materials segment is primarily attributed to increased selling prices of
The operating income decrease is primarily attributed to a
Cash Flow and Balance Sheet
Our cash flow from operating activities decreased to
Our total debt less cash and cash equivalents (or “net debt”) at the end of the
In
Fiscal 2021 Guidance
Given our continued strength and stable demand outlook across our businesses, we are increasing our operating EBITDA guidance to
Investor Conference Call
The Company will host a conference call today,
About Berry
At
Non-GAAP Financial Measures and Estimates
This press release includes non-GAAP financial measures such as operating EBITDA, Adjusted EBITDA, Adjusted net income, and free cash flow. A reconciliation of these non-GAAP financial measures to comparable measures determined in accordance with accounting principles generally accepted in
Forward Looking Statements
Statements in this release that are not historical, including statements relating to the expected future performance of the Company, are considered “forward looking” within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “could,” “seeks,” “approximately,” “intends,” “plans,” “projects,” “estimates,” “projects,” “outlook,” “anticipates” or “looking forward,” or similar expressions that relate to our strategy, plans, intentions, or expectations. All statements we make relating to our estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates, and financial results or to our expectations regarding future industry trends are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. These forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those that we expected. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results.
Important factors that could cause actual results to differ materially from our expectations, which we refer to as cautionary statements, are disclosed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K and subsequent filings with the
|
||||||||||||
Consolidated Statements of Income |
||||||||||||
(Unaudited) |
||||||||||||
(in millions of dollars, except per share data amounts) |
||||||||||||
|
Quarterly Period Ended |
|
Three Quarterly Periods Ended |
|||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|||||
|
|
|
|
|
|
|
|
|||||
Net sales |
$ |
3,675 |
|
$ |
2,910 |
|
|
$ |
10,181 |
|
$ |
8,701 |
Costs and expenses: |
|
|
|
|
|
|
|
|||||
Cost of goods sold |
|
3,049 |
|
|
2,272 |
|
|
|
8,273 |
|
|
6,959 |
Selling, general and administrative |
|
207 |
|
|
198 |
|
|
|
668 |
|
|
631 |
Amortization of intangibles |
|
72 |
|
|
74 |
|
|
|
219 |
|
|
226 |
Restructuring and transaction activities |
|
4 |
|
|
19 |
|
|
|
41 |
|
|
55 |
Operating income |
|
343 |
|
|
347 |
|
|
|
980 |
|
|
830 |
|
|
|
|
|
|
|
|
|||||
Other expense (income), net |
|
14 |
|
|
(7 |
) |
|
|
45 |
|
|
6 |
Interest expense, net |
|
76 |
|
|
110 |
|
|
|
257 |
|
|
339 |
Income before income taxes |
|
253 |
|
|
244 |
|
|
|
678 |
|
|
485 |
Income tax expense |
|
59 |
|
|
53 |
|
|
|
173 |
|
|
121 |
Net income |
$ |
194 |
|
$ |
191 |
|
|
$ |
505 |
|
$ |
364 |
|
|
|
|
|
|
|
|
|||||
Net income per share: |
|
|
|
|
|
|
|
|||||
Basic |
$ |
1.44 |
|
$ |
1.44 |
|
|
$ |
3.76 |
|
$ |
2.75 |
Diluted |
|
1.40 |
|
|
1.42 |
|
|
|
3.67 |
|
|
2.71 |
|
|
|
|
|
|
|
|
|||||
Outstanding weighted-average shares: (in millions) |
|
|
|
|
|
|
|
|||||
Basic |
|
135.1 |
|
|
132.5 |
|
|
|
134.3 |
|
|
132.4 |
Diluted |
|
138.5 |
|
|
134.2 |
|
|
|
137.7 |
|
|
134.3 |
|
|
|
|
|
|
|
|
|
|||||
Condensed Consolidated Balance Sheets |
|||||
(Unaudited) |
|||||
(in millions of dollars) |
|||||
|
|
|
|
||
Assets: |
|
|
|
||
Cash and cash equivalents |
$ |
804 |
|
$ |
750 |
Accounts receivable, net |
|
1,851 |
|
|
1,469 |
Inventories |
|
1,735 |
|
|
1,268 |
Other current assets |
|
198 |
|
|
330 |
Property, plant, and equipment, net |
|
4,731 |
|
|
4,561 |
|
|
8,258 |
|
|
8,323 |
Total assets |
$ |
17,577 |
|
$ |
16,701 |
|
|
|
|
||
Liabilities and Stockholders' Equity: |
|
|
|
||
Current liabilities, excluding debt |
$ |
2,654 |
|
$ |
2,108 |
Current and long-term debt |
|
9,694 |
|
|
10,237 |
Other long-term liabilities |
|
2,276 |
|
|
2,264 |
Stockholders’ equity |
|
2,953 |
|
|
2,092 |
Total liabilities and stockholders' equity |
$ |
17,577 |
|
$ |
16,701 |
|
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(Unaudited) |
|||||||
(in millions of dollars) |
|||||||
|
Three Quarterly Periods Ended |
||||||
|
|
|
|
||||
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
505 |
|
|
$ |
364 |
|
Adjustments to reconcile net cash provided by operating activities: |
|
|
|
||||
Depreciation |
|
420 |
|
|
|
412 |
|
Amortization of intangibles |
|
219 |
|
|
|
226 |
|
Non-cash interest |
|
26 |
|
|
|
18 |
|
Deferred income tax |
|
(53 |
) |
|
|
30 |
|
Share-based compensation expense |
|
34 |
|
|
|
28 |
|
Other non-cash operating activities, net |
|
60 |
|
|
|
23 |
|
Changes in working capital |
|
(278 |
) |
|
|
(93 |
) |
Changes in other assets and liabilities |
|
(21 |
) |
|
|
(29 |
) |
Net cash from operating activities |
|
912 |
|
|
|
979 |
|
|
|
|
|
||||
Cash flows from investing activities: |
|
|
|
||||
Additions to property, plant, and equipment, net |
|
(520 |
) |
|
|
(419 |
) |
Divestiture of businesses |
|
165 |
|
|
|
— |
|
Settlement of net investment hedges |
|
— |
|
|
|
281 |
|
Other investing activities |
|
— |
|
|
|
(14 |
) |
Net cash from investing activities |
|
(355 |
) |
|
|
(152 |
) |
|
|
|
|
||||
Cash flows from financing activities: |
|
|
|
||||
Repayments on long-term borrowings |
|
(3,287 |
) |
|
|
(1,859 |
) |
Proceeds from long-term borrowings |
|
2,716 |
|
|
|
1,202 |
|
Proceeds from issuance of common stock |
|
57 |
|
|
|
6 |
|
Debt financing costs |
|
(20 |
) |
|
|
(16 |
) |
Net cash from financing activities |
|
(534 |
) |
|
|
(667 |
) |
Effect of currency translation on cash |
|
31 |
|
|
|
(4 |
) |
Net change in cash and cash equivalents |
|
54 |
|
|
|
156 |
|
Cash and cash equivalents at beginning of period |
|
750 |
|
|
|
750 |
|
Cash and cash equivalents at end of period |
$ |
804 |
$ |
906 |
|
||||||||||||||
Condensed Consolidated Financial Statements |
||||||||||||||
Segment Information |
||||||||||||||
(Unaudited) |
||||||||||||||
(in millions of dollars) |
||||||||||||||
|
Quarterly Period Ended |
|||||||||||||
|
Consumer
|
|
Consumer
|
|
Health,
|
|
Engineered
|
|
Total |
|||||
Net sales |
$ |
1,095 |
|
$ |
847 |
|
$ |
828 |
|
$ |
905 |
|
$ |
3,675 |
|
|
|
|
|
|
|
|
|
|
|||||
Operating income |
$ |
79 |
|
$ |
76 |
|
$ |
113 |
|
$ |
75 |
|
$ |
343 |
Depreciation and amortization |
|
88 |
|
|
53 |
|
|
43 |
|
|
28 |
|
|
212 |
Restructuring and transaction activities (1) |
|
3 |
|
|
— |
|
|
— |
|
|
1 |
|
|
4 |
Other non-cash charges (2) |
|
2 |
|
|
2 |
|
|
1 |
|
|
1 |
|
|
6 |
Operating EBITDA |
$ |
172 |
|
$ |
131 |
|
$ |
157 |
|
$ |
105 |
|
$ |
565 |
|
|
|
|
|
|
|
|
|
|
|
Quarterly Period Ended |
|||||||||||||
|
Consumer
|
|
Consumer
|
|
Health,
|
|
Engineered
|
|
Total |
|||||
Net sales |
$ |
904 |
|
$ |
644 |
|
$ |
669 |
|
$ |
693 |
|
$ |
2,910 |
|
|
|
|
|
|
|
|
|
|
|||||
Operating income |
$ |
80 |
|
$ |
78 |
|
$ |
95 |
|
$ |
94 |
|
$ |
347 |
Depreciation and amortization |
|
78 |
|
|
58 |
|
|
45 |
|
|
28 |
|
|
209 |
Restructuring and transaction activities (1) |
|
14 |
|
|
2 |
|
|
1 |
|
|
2 |
|
|
19 |
Other non-cash charges (2) |
|
2 |
|
|
2 |
|
|
1 |
|
|
1 |
|
|
6 |
Operating EBITDA |
$ |
174 |
|
$ |
140 |
|
$ |
142 |
|
$ |
125 |
|
$ |
581 |
(1) |
The current quarter primarily includes transaction activity costs related to the RPC acquisition. The prior year quarter primarily includes transaction activity costs related to the RPC acquisition. |
|
(2) |
Other non-cash charges for the |
|
Note: For comparison purposes to the |
|
|||||||||||
Reconciliation Schedules |
|||||||||||
(Unaudited) |
|||||||||||
(in millions of dollars, except per share data) |
|||||||||||
|
Quarterly Period Ended |
|
Four Quarters Ended |
|
|||||||
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|||||
Net income |
$ |
194 |
|
$ |
191 |
|
|
$ |
715 |
|
|
Add: other expense, net |
|
14 |
|
|
(7 |
) |
|
|
70 |
|
|
Add: interest expense, net |
|
76 |
|
|
110 |
|
|
|
353 |
|
|
Add: income tax expense |
|
59 |
|
|
53 |
|
|
|
206 |
|
|
Operating income |
$ |
343 |
|
$ |
347 |
|
|
$ |
1,344 |
|
|
|
|
|
|
|
|
|
|||||
Add: non-cash amortization from 2006 private sale |
|
6 |
|
|
6 |
|
|
|
24 |
|
|
Add: restructuring and transaction activities (1) |
|
4 |
|
|
19 |
|
|
|
48 |
|
|
Add: other non-cash charges (2) |
|
6 |
|
|
6 |
|
|
|
42 |
|
|
Adjusted operating income (6) |
$ |
359 |
|
$ |
378 |
|
|
$ |
1,458 |
|
|
|
|
|
|
|
|
|
|||||
Add: depreciation |
|
140 |
|
|
135 |
|
|
|
553 |
|
|
Add: amortization of intangibles (3) |
|
66 |
|
|
68 |
|
|
|
269 |
|
|
Operating EBITDA (6) |
$ |
565 |
|
$ |
581 |
|
|
$ |
2,280 |
|
|
|
|
|
|
|
|
|
|||||
Less: divestitures (4) |
|
|
|
|
|
(13 |
) |
|
|||
Adjusted EBITDA (6) |
|
|
|
|
$ |
2,267 |
|
|
Cash flow from operating activities |
|
|
|
|
$ |
1,463 |
|
|
Net additions to property, plant, and equipment |
|
|
|
|
|
(684 |
) |
|
Free cash flow (6) |
|
|
|
|
$ |
779 |
|
|
|
|
|
|
|
|
|
Net income per diluted share |
$ |
1.40 |
|
|
$ |
1.42 |
|
|
|
Other expense, net |
|
0.10 |
|
|
|
(0.05 |
) |
|
|
Non-cash amortization from 2006 private sale |
|
0.04 |
|
|
|
0.04 |
|
|
|
Restructuring and transaction activities |
|
0.03 |
|
|
|
0.14 |
|
|
|
Income tax impact on items above (5) |
|
(0.04 |
) |
|
|
(0.03 |
) |
|
|
Adjusted net income per diluted share (6) |
$ |
1.53 |
|
|
$ |
1.52 |
|
|
|
|
|
|
|
|
|
Estimated Fiscal 2021 |
|||
Cash flow from operating activities |
$ |
1,575 |
|
|
Additions to property, plant, and equipment |
|
(700 |
) |
|
Free cash flow (6) |
$ |
875 |
|
(1)
|
The current quarter primarily includes transaction activity costs related to the RPC acquisition. The prior year quarter primarily includes transaction activity costs related to the RPC acquisition. |
|
(2)
|
Other non-cash charges for the |
|
(3) |
Amortization excludes non-cash amortization from the 2006 private sale of |
|
(4) |
Represents earnings related to divestments within the last twelve months. |
|
(5) |
Income tax effects on adjusted net income is calculated using 25 percent for both the |
|
(6) |
Supplemental financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in |
|
|
|
|
|
We define “free cash flow” as cash flow from operating activities less additions to property, plant, and equipment. We believe free cash flow is useful to an investor in evaluating our liquidity because free cash flow and similar measures are widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s liquidity. We also believe free cash flow is useful to an investor in evaluating our liquidity as it can assist in assessing a company’s ability to fund its growth through its generation of cash. |
|
|
|
|
|
Adjusted EBITDA is used by our lenders for debt covenant compliance purposes. We also use Adjusted EBITDA and Operating EBITDA among other measures to evaluate management performance and in determining performance-based compensation. Adjusted EBITDA and Operating EBITDA and similar measures are widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s performance. We also believe EBITDA and Adjusted net income are useful to an investor in evaluating our performance without regard to revenue and expense recognition, which can vary depending upon accounting methods. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005200/en/
Company Contact:
+1 (812) 306 2964
ir@berryglobal.com
Source: